Vaxcyte, Inc. $PCVX Stock Holdings Increased by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its holdings in Vaxcyte, Inc. by 60.5% during the 2nd quarter, acquiring an additional 160,170 shares, bringing its total ownership to approximately 0.33% of the company.
• Vaxcyte reported a quarterly earnings per share (EPS) of ($1.22), which missed analysts' estimates by ($0.10), as analysts project a current year EPS of (-4.21).
• According to equity analysts, the stock has an average rating of "Moderate Buy" with a consensus price target of $106.25, while several firms have issued mixed ratings, including a "neutral" rating from Goldman Sachs.

Aberdeen Group plc raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 60.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 424,907 shares of the company's stock after acquiring an additional 160,170 shares during the period. Aberdeen Group plc owned approximately 0.33% of Vaxcyte worth $13,814,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in Vaxcyte by 5.5% during the 1st quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock valued at $6,843,000 after acquiring an additional 9,416 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in shares of Vaxcyte by 32.8% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 102,362 shares of the company's stock valued at $3,328,000 after purchasing an additional 25,303 shares during the period. Intech Investment Management LLC increased its position in shares of Vaxcyte by 44.3% during the 1st quarter. Intech Investment Management LLC now owns 89,212 shares of the company's stock valued at $3,369,000 after purchasing an additional 27,384 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Vaxcyte by 5.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,110 shares of the company's stock valued at $459,000 after purchasing an additional 772 shares during the period. Finally, Strs Ohio acquired a new position in shares of Vaxcyte during the 1st quarter valued at $627,000. Institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Down 2.2%

Shares of Vaxcyte stock opened at $42.85 on Wednesday. The stock's fifty day moving average is $33.86 and its 200-day moving average is $33.54. The firm has a market capitalization of $5.56 billion, a PE ratio of -10.43 and a beta of 1.12. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $118.62.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the business earned ($1.10) earnings per share. Analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PCVX shares. The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, September 12th. They set a "neutral" rating and a $38.00 price target on the stock. Cowen reiterated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Vaxcyte in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $106.25.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.